SLP Stock - Simulations Plus, Inc.
Unlock GoAI Insights for SLP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $79.18M | $70.01M | $59.58M | $53.91M | $46.47M |
| Gross Profit | $46.22M | $43.15M | $47.95M | $43.08M | $35.87M |
| Gross Margin | 58.4% | 61.6% | 80.5% | 79.9% | 77.2% |
| Operating Income | $6.59M | $6.13M | $8.72M | $14.91M | $11.25M |
| Net Income | $-64,718,000 | $9.95M | $9.96M | $12.48M | $9.78M |
| Net Margin | -81.7% | 14.2% | 16.7% | 23.2% | 21.1% |
| EPS | $-3.22 | $0.50 | $0.50 | $0.62 | $0.49 |
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 18th 2025 | BTIG Research | Downgrade | Neutral | - |
| September 30th 2025 | TD Cowen | Initiation | Hold | $16 |
| July 15th 2025 | KeyBanc Capital Markets | Downgrade | Sector Weight | - |
| November 15th 2024 | Stephens | Initiation | Overweight | $39 |
| July 29th 2024 | KeyBanc Capital Markets | Initiation | Overweight | $47 |
| July 16th 2024 | JMP Securities | Initiation | Market Perform | - |
| June 28th 2024 | William Blair | Initiation | Outperform | - |
| May 9th 2023 | BTIG Research | Initiation | Buy | $55 |
Earnings History & Surprises
SLPEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 1, 2026 | — | — | — | — |
Q1 2026 | Jan 8, 2026 | $0.18 | — | — | — |
Q4 2025 | Oct 22, 2025 | $0.07 | $0.06 | -14.3% | ✗ MISS |
Q3 2025 | Jul 14, 2025 | $0.26 | $0.45 | +73.1% | ✓ BEAT |
Q2 2025 | Apr 3, 2025 | $0.25 | $0.31 | +24.0% | ✓ BEAT |
Q1 2025 | Jan 7, 2025 | $0.18 | $0.17 | -5.6% | ✗ MISS |
Q4 2024 | Oct 23, 2024 | $0.07 | $0.06 | -9.1% | ✗ MISS |
Q3 2024 | Jul 2, 2024 | $0.15 | $0.15 | 0.0% | = MET |
Q2 2024 | Apr 3, 2024 | $0.19 | $0.20 | +5.3% | ✓ BEAT |
Q1 2024 | Jan 3, 2024 | $0.10 | $0.10 | 0.0% | = MET |
Q4 2023 | Oct 25, 2023 | $0.18 | $0.18 | 0.0% | = MET |
Q3 2023 | Jul 6, 2023 | $0.20 | $0.20 | 0.0% | = MET |
Q2 2023 | Apr 5, 2023 | $0.18 | $0.20 | +11.1% | ✓ BEAT |
Q1 2023 | Jan 4, 2023 | $0.09 | $0.06 | -33.3% | ✗ MISS |
Q4 2022 | Oct 26, 2022 | $0.09 | $0.07 | -22.2% | ✗ MISS |
Q3 2022 | Jul 6, 2022 | $0.18 | $0.20 | +11.1% | ✓ BEAT |
Q2 2022 | Apr 6, 2022 | $0.14 | $0.21 | +50.0% | ✓ BEAT |
Q1 2022 | Jan 6, 2022 | $0.09 | $0.15 | +66.7% | ✓ BEAT |
Q4 2021 | Oct 25, 2021 | $0.08 | $0.01 | -87.5% | ✗ MISS |
Q3 2021 | Jul 12, 2021 | $0.18 | $0.18 | 0.0% | = MET |
Latest News
BTIG Downgrades Simulations Plus to Neutral
➖ NeutralSimulations Plus Responds To FDA Draft Guidance On Streamlined Nonclinical Safety Studies For Monoclonal Antibodies
➖ NeutralSimulations Plus Non-GAAP EPS of $0.10 misses by $0.02, revenue of $17.5M beats by $0.11M
➖ NeutralSimulations Plus Affirms FY2026 Adj EPS Guidance of $1.03-$1.10 vs $(3.22) Est; Affirms FY2026 Sales Guidance of $79.000M-$82.000M vs $78.797M Est
📈 PositiveSimulations Plus Q4 Adj. EPS $0.10 Beats $(0.05) Estimate, Sales $17.500M Beat $17.095M Estimate
📈 PositiveWatching Simulations Plus; Hearing Zacks HomeRun Newsletter Mentions Stock As A Buy
📈 PositiveSimulations Plus shares are trading higher after the company issued FY26 guidance.
📈 PositiveSimulations Plus Sees Prelim. FY26 Adj. EPS $1.03–$1.10, Revenue $79M-$82M
➖ NeutralTD Cowen Initiates Coverage On Simulations Plus with Hold Rating, Announces Price Target of $16
➖ NeutralNoble Corporation, Q2 Holdings, Waystar Holding And Hecla Mining Will Replace Owens & Minor, B&G Food, Jack In The Box And Simulations Plus In The S&P SmallCap 600, Respectively
➖ NeutralSimulations Plus Non-GAAP EPS of $0.45 beats by $0.20, revenue of $20.36M beats by $0.77M
📈 PositiveSimulations Plus shares drop over 12% premarket as Q3 revenue forecast misses expectations
📉 NegativeFrequently Asked Questions about SLP
What is SLP's current stock price?
What is the analyst price target for SLP?
What sector is Simulations Plus, Inc. in?
What is SLP's market cap?
Does SLP pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SLP for comparison